Hehenberger Nanomedicine

Science, Business, and Impact
Erscheinungsjahr 2015
ISBN: 978-981-4613-77-4
Verlag: Pan Stanford Publishing
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 428 Seiten

By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients, and for close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of nanomedicine in detail to help understand the great promise of nanomedicine across all disease areas. Although rich and deep in content, the book attempts to introduce the topic of nanomedicine to a wide audience. Scientific jargon is avoided and advanced terms and concepts are explained from the ground up, whenever first introduced.

The book defines nanomedicine in a broad sense, including diagnostic devices such as DNA sequencing and molecular imaging, and new therapeutic options based on targeted drug delivery, regenerative medicine, immunotherapeutics, the creation of implanted devices such as continuous glucose monitors and deep brain stimulators, and even the 3D printing of new human organs. It also covers the returns of investment in global scientific projects, such as the Human Genome Project, and the historic and emerging importance of philanthropic foundations.

Autoren/Hrsg.

Hehenberger, Michael

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie Medizinische Biotechnologie

Inhaltsverzeichnis

Dedication

Purpose

Table of Contents

Introduction

What is Nanomedicine?

What is Translational Medicine?

What is Innovation?

What is Intellectual Property?

From IP to IPO

What is Impact?

From Atoms to Proteins

Atoms and Molecules

Atoms of Life

Molecules of Life

Proteins

Genetics and DNA Sequencing

DNA and the Genetic Code

From DNA to Proteins and Cells

History of Genetics

Molecular Basis of Genetics

DNA Sequencing and the Human Genome Project

Sequencing Technologies

Chemical Sequencing

Sanger Sequencing, NGS and the $1,000 Genome Challenge

Second Generation DNA Sequencing

Third Generation DNA Sequencing

Fourth Generation DNA Sequencing

Sequencing Data Analysis

Bioethics

Business Aspects of Sequencing Technology and the Human Genome Project

Post Human Genome Project: "Omics"

Bio-Pharmaceutical R&D

Stages of Bio-Pharmaceutical Drug Discovery and Clinical Development

Stage 1: Drug Discovery

Stage 2: Pre-Clinical Research

Stages 3–4: Clinical Trials and FDA Review

The Emerging Importance of "Biologics"

Biomarkers and Stratified/Personalized Medicine

The Past and Future of Bio-Pharmaceutical R&D

Semiconductors: Progress through Collaboration

Life Sciences Industry: Exclusive IP Deals and Limited Collaboration

IMI and AMP

Nanomedicine

Computers in Nanomedicine

Biocompatible Nanoparticles and Targeted Drug Delivery

Dendrimers

Liposomes

Targeted Drug Delivery

The Business of Nanotherapeutics

Biomedical and Molecular Imaging

Nanodiagnostics

Regenerative Medicine: Stem Cells, Gene Therapy, Immunotherapy

Impact of Nanomedicine

The Gut Microbiome

Central Nervous System: Brain and Spinal Cord

Cancer and Immunology

Cardiovascular Disease

Diabetes

Infectious Disease

Tissue and Organ Transplantation

The Healthcare Ecosystem AND BIOMEDICAL RESEARCH FUNDING

It’s all about the Patient/Consumer

The Future of Funding for Basic Biomedical and Translational Research

Public Health and Global Health Economics

Global View of Healthcare Costs, Infant Mortality and Life Expectancy

US Health Statistics

Conclusions

Acknowledgments

References

Über Autor(innen)

Michael Hehenberger left IBM in 2013 and founded HM NanoMed LLC, based in Westport, Connecticut. After earning an engineering degree in physics from TU Vienna, Austria, he obtained his Ph.D. and "docent" degrees in quantum chemistry from Uppsala University, Sweden. He also spent two years at the University of Florida, Gainesville, as visiting associate professor. In 1985, Dr. Hehenberger joined IBM in Sweden to initiate academic partnerships in computational chemistry, biology, structural engineering, and campus computing networks. Throughout his career that took him to European headquarters in Paris, to IBM Almaden Research (San Jose, California), and to New York, he has led research collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational science, information-based medicine, text analytics, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.